MedTrace Logo

Long-Term Follow-Up Study of Patients Receiving ATL001

NCT04785365 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-11-21

No results posted yet for this study

Summary

This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001 (NCT03997474).

Conditions

  • Melanoma
  • Advanced Non Small Cell Lung Cancer

Interventions

OTHER

Biological: ATL001

No investigational product will be administered

Sponsors & Collaborators

  • Achilles Therapeutics UK Limited

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Achilles Therapeutics UK Limited

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-10-18
Completion
2023-10-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04785365 on ClinicalTrials.gov